ScreenerHero

EGRX Eagle Pharmaceuticals, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · eagleus.com
1.285USD0.00%Mkt Cap: 3.29M $P/E: 0.74

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap3.29M USD
Enterprise Value69.70M USD
Revenue (TTM)257.55M USD
Gross Profit221.67M USD
Net Income (TTM)35.64M USD
Revenue/Share19.68 USD
Last Price1.285 USD
Fiscal Year EndDec 2022
MR QuarterJun 2023
Employees134
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS2697961082
Valuation
P/E (Trailing)0.74
P/E (Forward)0.07
PEG—
EV/EBITDA1.12
EV/Revenue0.27
P/S0.01
P/B0.01
EPS (TTM)1.77
EPS (Forward)3.48
52W Range
0.001034% of range3.725
52W High3.725 USD
52W Low0.0010 USD
Profitability
Gross Margin70.01%
Oper. Margin15.94%
EBITDA Margin24.20%
Profit Margin11.26%
ROE15.26%
ROA8.78%
Growth
Revenue Growth-12.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF50.70M USD
CapEx (TTM)178.00K USD
FCF Margin14.88%
FCF Yield1164.80%
Net Debt57.10M USD
Net Debt/EBITDA0.92
Balance Sheet
Debt/Equity0.27
Current Ratio2.16
Quick Ratio1.51
Book Value/Sh19.25 USD
Cash/Share1.18 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.16M
Float7.39M
Insiders0.00%
Institutions43.35%
Short Interest
Short Ratio4.1d
Short % Float4.44%
Short % Out.2.87%
Shares Short371.55K
Short (prev mo.)423.83K
Technical
SMA 500.6955 (+84.8%)
SMA 2000.4779 (+168.9%)
Beta0.87
S&P 52W Chg16.45%
Avg Vol (30d)1.38K
Avg Vol (10d)3.26K
Technical Indicators
RSI (14)65.2
MACD0.1726
MACD Signal0.1123
MACD Hist.+0.0604
BB Upper1.416 USD
BB Middle0.8061 USD
BB Lower0.1964 USD
BB Width151.27%
ATR (14)0.2309 USD
Vol Ratio (20d)0.00x